课题基金 / 基金详情

Training Program in Molecular Oncology and Immunology

Training Program in Molecular Oncology and Immunology
分子肿瘤学和免疫学培训计划
批准号:
7271842
负责人:
ANGEL PELLICER
金额:
$77.47万
依托单位国家:
美国
项目类别:
财政年份:
1985
资助国家:
美国
项目状态:
已结题
起止时间:
1985-09-30 至 2010-06-30

项目摘要

项目成果

ANGEL PELLICER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This proposal requests funds to continue support for training of 7 predoctoral and 8 postdoctoral fellows (PhD or MD) in the areas of molecular oncology and immunology. Particular emphasis is placed on a combined education in these disciplines for a better understanding of the regulatory mechanisms involved in cellular transformation and immunological cell response. Cross-fertilization of these disciplines allows development of entirely new approaches to studies both of oncogenes and of immunologically cells in its normal state or in tumors and fosters the development of translational research in cancer. The unique aspects of this program is that the trainees are required to become proficient in the basics of both immunology and molecular oncology; the students are then directed to focus in one of these two areas with strong emphasis on cancer related projects. Thirty-eight faculty members from the Departments of Pathology, Cell Biology, Biochemistry, Pharmacology, Medicine, Radiation Oncology, Dermatology, Radiology and Microbiology participate in this program. The program is under the aegis of both the Sackler Institute for Basic Medical Sciences and the NYU Cancer Institute and has expanded with the new faculty recruited for the Skirball Institute of Biomolecular Medicine and the A. Diamond Professorships in Immunology. It will continue to expand with opening of the Smilow building, presently under construction, and which will dedicate three of its floors to cancer research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PATHWAYS OF BLADDER TUMORIGENESIS
PATHWAYS OF BLADDER TUMORIGENESIS
DMBA INDUCED SELF REGRESSING TUMORS--ROLE OF H-RAS
RGR--A NOVEL ONCOGENE IN THE RAL PATHWAY
海外基金